What is the Advantage of Administering a Beta-Lactam with a Beta-Lactamase Inhibitor?
OCT 13, 2017 | CONTAGION® EDITORIAL STAFF
Amanda Paschke, MD, MSCE, director of Clinical Research, Infectious Diseases, at Merck, breaks down the advantages of administering a beta-lactam in combination with a beta-lactamase inhibitor. Dr. Paschke highlights Merck’s development compound imipenem-relebactam, and explains how relebactam restores susceptibility to imipenem.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512